Minority enrollment in Parkinson's disease clinical trials

Parkinsonism and Related Disorders

Volumn 15, Issue 4, 2009, Pages 258-262

  Schneider, Myra G ^a   Swearingen, Christopher J ^b   Shulman, Lisa M ^a   Ye, Jian ^a   Baumgarten, Mona ^a   Tilley, Barbara C ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Clinical trials; Health disparities; Minority enrollment; Parkinson's disease

Indexed keywords

ARTICLE; CLINICAL RESEARCH; COMORBIDITY; DATA BASE; ETHNIC AND RACIAL GROUPS; ETHNIC DIFFERENCE; HUMAN; MINORITY GROUP; PARKINSON DISEASE; PRIORITY JOURNAL; PUBLICATION; SCREENING;

CLINICAL TRIALS AS TOPIC; HEALTH SERVICES ACCESSIBILITY; HUMANS; MINORITY GROUPS; PARKINSON DISEASE; PUBMED; UNITED STATES;

EID: 64249133367     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2008.06.005     Document Type: Article

References (73)

1. Marras C., Rochon P., and Lang A.E. Predicting motor decline and disability in Parkinson disease: a systematic review. Arch Neurol 59 11 (2002) 1724-1728
2. Jankovic J., and Kapadia A.S. Functional decline in Parkinson disease. Arch Neurol 58 10 (2001) 1611-1615
3. Pressley J.C., Louis E.D., Tang M.X., Cote L., Cohen P.D., Glied S., et al. The impact of comorbid disease and injuries on resource use and expenditures in parkinsonism. Neurology 61 7 (2003) 87-93
4. de Lau L.M., and Breteler M.M. Epidemiology of Parkinson's disease. Lancet Neurol 5 6 (2006) 525-535
5. Mayeux R. Epidemiology of neurodegeneration. Annu Rev Neurosci 26 (2003) 81-104
6. Zhang Z.X., and Roman G.C. Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology 12 (1993) 195-208
7. Van Den Eeden S.K., Tanner C.M., Bernstein A.L., Fross R.D., Leimpeter A., Bloch D.A., et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 157 11 (2003) 1015-1022
8. McInerney-Leo A., Guinn-Hardy K., and Unssbaum R.L. Prevalence of Parkinson's disease in populations of African ancestry: a review. J Natl Med Assoc 96 7 (2004) 974-979
9. Mosenfar Z. Population issues in clinical trials. Proc Am Thorac Soc 4 2 (2007) 185-187
10. NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66 5 (2006) 664-671
11. NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in Parkinson disease. Neurology 68 1 (2007) 20-28
12. Parkinson Study Group. Pramipexole in levodopa-treated Parkinson disease patients of African, Asian and Hispanic heritage. Clin Neuropharmacol 20 2 (2007) 72-85
13. Mercer B.S. A randomized study of the efficacy of the PROPATH program for patients with Parkinson disease. Arch Neurol 53 9 (1996) 881-884
14. Damiano A.M., McGrath M.M., Willian M.K., Snyder C.F., LeWitt P.A., Reyes P.F., et al. Evaluation of a measurement strategy for Parkinson's disease: assessing patient health-related quality of life. Qual Life Res 9 1 (2000) 87-100
15. Breier A., Sutton V.K., Feldman P.D., Kadam D.L., Ferchland I., Wright P., et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry 52 5 (2002) 438-445
16. Vitek J.L., Bakay R.A., Freeman A., Evatt M., Green J., McDonald W., et al. Randomized trial of pallidotomy versus medical therapy for Parkinson's disease. Ann Neurol 53 5 (2003) 558-569
17. McRae C., Cherin E., Yamazaki T.G., Diem G., Vo A.H., Russell D., et al. Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial. Arch Gen Psychiatry 61 4 (2004) 412-420
18. Olanow C.W., Schapira A.H., LeWitt P.A., Kieburtz K., Sauer D., Olivieri G., et al. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomized controlled trial. Lancet Neurol 5 12 (2006) 1013-1020
19. Pfeiffer R.F., Gutmann L., Hull K.L., Bottini P.B., and Sherry J.H. Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease. Parkinsonism Relat Disord 13 2 (2007) 93-100
20. Pahwa R., Koller W.C., Trosch R.M., and Sherry J.H. Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose. J Neurol Sci 258 1-2 (2007) 137-143
21. Lew M.F., Pahwa R., Leehey M., Bertoni J., and Kricorian G. Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease. Curr Med Res Opin 23 4 (2007) 741-750
22. U.S. Census Bureau, 2005 American Community Survey (ACS).
23. Grann V.R., Jacobson J.S., Troxel A.B., Hershman D., Karp J., Myers C., et al. Barriers to minority participation in breast carcinoma prevention trials. Cancer 104 2 (2005) 374-379
24. Tilley B.C., Wisdom K., Sadler Z.E., and Bradford W.D. Overcoming barriers to the inclusion of older African Americans in health outcomes research. In: Curry L., and Jackson J. (Eds). The science of inclusion: recruiting and retaining racial and ethnic elders in health research (2004), The Gerontological Society of America, Washington DC 63-71
25. Ford J.G., Howerton M.W., Bolen S., Gary T.L., Lai G.Y., Tilburt J., et al. Knowledge and access to information on recruitment of underrepresented populations to cancer clinical trials. Evid Rep Technol Assess (Summ) 122 (2005) 1-11
26. Swanson G.M., and Ward A.J. Recruiting minorities into clinical trials: toward a participant-friendly system. J Natl Cancer Inst 87 23 (1995) 1747-1759
27. Cook E.D., Moody-Thomas S., Anderson K.B., Campbell R., Hamilton S.J., Harrington J.M., et al. Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Clin Trials 2 5 (2005) 436-442
28. Wendler D., Kington R., Madans J., Van Wye G., Christ-Schmidt H., Pratt L.A., et al. Are racial and ethnic minorities less willing to participate in health research?. PLoS Med 3 2 (2006 Feb) e19 Epub 2005 Dec 6
29. Bluestein J., and Weiss L.J. Visits to specialists under Medicare: socioeconomic advantage and access to care. J Health Care Poor Underserved 9 (1998) 153-169
30. Bach P.B., Pham H.H., Schrag D., Tate R.C., and Hargraves J.L. Primary care physicians who treat blacks and whites. N Engl J Med 351 6 (2004) 575-584
31. Kumanyika S., Savage D.D., Ramirez A.G., Hutchinson J., Trevino F.M., Adams-Campbell L.L., et al. Beliefs about high blood pressure prevention in a survey of blacks and Hispanics. Am J Prev Med 5 1 (1989) 21-26
32. Werner P. Knowledge about symptoms of Alzheimer's disease: correlates and relationship to help-seeking behavior. Int J Geriatr Psychiatry 18 11 (2003) 1029-1036
33. Schenkman M., Cutson T.M., Zhu C.W., and Whetten-Goldstein K. A longitudinal evaluation of patients' perceptions of Parkinson's disease. Gerontologist 42 6 (2002) 790-798
34. Curry L., and Jackson J. Recruitment and retention of diverse ethnic and racial groups in health research: an evolving science. In: Curry L., and Jackson J. (Eds). The science of inclusion: recruiting and retaining racial and ethnic elders in health research (2004), The Gerontological Society of America, Washington DC 1-7
35. Ballard E.L., Nash F., Raiford K., and Harrell L.E. Recruitment of black elderly for clinical research studies of dementia: the CERAD experience. Gerontologist 33 4 (1993) 561-565
36. Levkoff S., and Sanchez H. Lessons learned about minority recruitment and retention from the centers on minority aging and health promotion. Gerontologist 43 (2003) 18-26
37. Goodwin J.S., Black S.A., and Satish S. Aging versus disease: the opinions of older black, Hispanic, and non-Hispanic white Americans about the causes and treatment of common medical conditions. J Am Geriatr Soc 47 8 (1999) 973-979
38. Tanner C.M., and Goldman S.M. Epidemiology of Parkinson's disease. Neurol Clin 14 2 (1996) 317-335
39. Murthy V.H., Krumholz H.M., and Gross C.P. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 291 22 (2004) 2720-2726
40. Ford M.E., Havstad S.L., and Davis S.D. A randomized trial of recruitment methods for older African American men in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Clin Trials 1 (2004) 343-351
41. Unson C.G., Ohannessian C., Kenyon L., Case A., Reisine S., and Prestwood K. Barriers to eligibility and enrollment among older women in a clinical trial on osteoporosis: effects of ethnicity and SES. J Aging Health 16 3 (2004) 426-443
42. Coleman E.A., Tyll L., LaCroix A.Z., Allen C., Leveille S.G., Wallace J.I., et al. Recruiting African American older adults for a community-based health promotion intervention: which strategies are effective?. Am J Prev Med 13 (1997) 51-56
43. Vesey G.A. Recruitment and retention of minority elders in health-related research: a community-based approach. In: Curry L., and Jackson J. (Eds). The science of inclusion: recruiting and retaining racial and ethnic elders in health research (2004), Gerontological Society of America, Washington DC 82-89
44. Bain L.J. Crossroads in clinical trials. NeuroRx 2 3 (2005) 525-528
45. Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. Arch Neurol 46 10 (1989) 1052-1060
46. Shoulson I., Oakes D., Fahn S., Lang A., Langston J.W., LeWitt P., et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 51 5 (2002) 604-612
47. Parkinson Study Group. A controlled trial of lazabemide (RO19-6327) in untreated Parkinson's disease. Parkinson Study Group. Ann Neurol 33 4 (1993) 350-356
48. Parkinson Study Group. A controlled trial of lazabemide (RO19-6327) in levodopa-treated Parkinson's disease. Parkinson Study Group. Arch Neurol 51 4 (1994) 342-347
49. Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group. JAMA 278 2 (1997) 125-130
50. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group. Ann Neurol 42 5 (1997) 747-755
51. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. The Parkinson Study Group. N Engl J Med 340 10 (1999) 757-763
52. Parkinson Study Group. A multicenter randomized controlled trial of remacemide hydrochloride as monotherapy for PD. Parkinson Study Group. Neurology 54 8 (2000) 1583-1588
53. Parkinson Study Group. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Parkinson Study Group. Clin Neuropharmacol 23 1 (2000) 34-44
54. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 284 15 (2000) 1931-1938
55. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287 13 (2002) 1653-1661
56. Holloway R.G., Shoulson I., Fahn S., Kieburtz K., Lang A., Marek K., et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 61 7 (2004) 1044-1053
57. Constantinescu R., Romer M., McDermott M.P., Kamp C., and Kieburtz K. Impact of pramipexole on the onset of levodopa-related dyskinesias. Mov Disord 22 9 (2007) 1317-1319
58. Parkinson Study Group. Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease. Arch Neurol 58 10 (2001) 1660-1668
59. Shoulson I., Penney J., McDermott M., Schwid S., Kayson E., Chase T., et al. A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease. Neurology 56 4 (2001) 455-462
60. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 59 12 (2002) 1937-1943
61. Siderowf A., McDermott M., Kieburtz K., Blindauer K., Plumb S., and Shoulson I. Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial. Mov Disord 17 4 (2002) 758-763
62. Biglan K.M., Schwid S., Eberly S., Blindauer K., Fahn S., Goren T., et al. Rasagiline improves quality of life in patients with early Parkinson's disease. Mov Disord 21 5 (2006) 616-623
63. deMarcaida J.A., Schwid S.R., White W.B., Blindauer K., Fahn S., Kieburtz K., et al. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord 21 10 (2006) 1716-1721
64. Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 60 12 (2003) 1721-1728
65. Trott C.T., Fahn S., Greene P., Dillon S., Winfield H., Winfield L., et al. Cognition following bilateral implants of embryonic dopamine neurons in PD: a double blind study. Neurology 60 12 (2003) 1938-1943
66. Fahn S., Oakes D., Shoulson I., Kieburtz K., Rudolph A., Lang A., et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 351 24 (2004) 2498-2508
67. Stern M.B., Marek K.L., Friedman J., Hauser R.A., LeWitt P.A., Tarsy D., et al. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. Mov Disord 19 8 (2004) 916-923
68. Friedman J.H., Berman R.M., Goetz C.G., Factor S.A., Ondo W.G., Wojcieszek J., et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord 21 12 (2006) 2078-2081
69. Watts R.L., Jankovic J., Waters C., Rajput A., Boroojerdi B., and Rao J. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 68 4 (2007) 272-276
70. Jankovic J., Watts R.L., Martin W., and Boroojerdi B. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson's disease. Arch Neurol 64 5 (2007) 676-682
71. Singer C., Lamb J., Ellis A., and Layton G. A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease. Mov Disord 22 4 (2007) 476-482
72. Parkinson Study Group. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 69 15 (2007) 1476-1477
73. Ondo W.G., Sethi K.D., and Kricorian G. Selegiline orally disintegrating tablets in patients with Parkinson disease and "wearing off" symptoms. Clin Neuropharmacol 30 5 (2007) 295-300